Moxifloxacin Hydrochloride CAS 186826-86-8 Raw Materials

CAS: 186826-86-8

MF: C48H48N4O6S2

Specification​: 99% min Moxifloxacin Hydrochloride Powder

Sample:  Moxifloxacin Hydrochloride Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Mebhydroline Napadisylate Usage and Synthesis:

Moxifloxacin Hydrochloride Powder is a fluoroquinolone antibiotic used to treat a variety of bacterial infections, including respiratory tract infections, skin and soft tissue infections, and urinary tract infections. It works by inhibiting the bacterial DNA synthesis, which ultimately leads to bacterial death. Moxifloxacin Hydrochloride Raw Materials is available in oral and injectable forms and is typically prescribed for short-term use. 

It is important to take the medication as prescribed and to complete the full course of treatment to ensure the infection is fully treated and to prevent the development of antibiotic resistance. Common side effects of moxifloxacin hydrochloride include nausea, diarrhea, headache, and dizziness. It is important to talk to a healthcare provider if any side effects are severe or persistent.

Pharmacokinetics of Mebhydroline Napadisylate:

Moxifloxacin hydrochloride is composed of is a fluoroquinolone antibiotic drug, the mechanism of action and in vitro antibacterial spectrum is similar to other fluoroquinolones, but the antibacterial activity against gram-positive and anaerobic bacteria is similar to that of trovafloxacin (trovafloxacin) and superior to some older species. Few Gram-positive bacteria were resistant to this product or resistance developed very slowly compared to other fluoroquinolones,

and cross-resistant bacteria were found in Gram-negative bacteria and enterococci compared to other fluoroquinolones. However, this product is at least effective against Staphylococcus aureus isolates grlA, grlB, gyrA or gyrB. This product 0.5~2mg/L can inhibit ciprofloxacin-resistant Staphylococcus aureus, which are ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin in descending order of MIC.

Clinical Application of Mebhydroline Napadisylate :

Moxifloxacin hydrochloride can be used for the treatment of socially acquired pneumonia, acute attacks of chronic bronchitis, acute sinusitis, etc. caused by Staphylococcus aureus, Mycobacterium influenzae, Pneumococcus pneumoniae, Moraxella mucosae, and Mycobacterium pneumoniae. Moxifloxacin tablets are used for the treatment of infections caused by sensitive bacteria in adults (≥18 years): e.g. acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, etc.

Moxifloxacin Hydrochloride Powder can be used for the treatment of community-acquired pneumonia caused by Staphylococcus aureus, Mycobacterium influenzae, Moraxella pneumoniae, Mycobacterium pneumoniae, acute exacerbation of chronic bronchitis, acute sinusitis, etc.

Moxifloxacin Hydrochloride Powder is an antibiotic used to treat bacterial infections of the lungs, paranasal sinuses, skin, and abdominal cavity in adults.

A fourth-generation ultra-broad-spectrum quinolone antibiotic use fluoroquinolone antibacterial agent, Urinary System Drugs Moxifloxacin Hydrochloride Powder is used to treat community-acquired pneumonia, acute exacerbations of chronic bronchitis, genitourinary infections, and acute sinusitis. It has significant efficacy and low adverse effects.